Hey Nosle, I was just throwing that out there as a model that worked for ELN, even though their drug failed. You are correct, PBT2 should be worth a lot more than Bapi with two successful trials behind it. Medivation negotiated 250m up front, keeping 40%, and the deal was only for 1 drug, and that worked very well for them. My opinion is that if a pharma comes in after 2 successful phase 2 trials, Prana should retain 50% or very close to it, as ELN did.
With that 259m up front I recall MDVN also had to contribute to trial costs.
I like your suggestion better if it is doable.
prana's future, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $8.4K | 2.1M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 79035427 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 115463117 | 7 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |